Tango Therapeutics
Investors
Join Us
Contact
Science
Approach
Platform
Publications + Posters
Pipeline
Programs
PRMT5
CoREST
Clinical Trials
Leadership
Home
Science
▼
Approach
Platform
Publications + Posters
Pipeline
Programs
▼
PRMT5
CoREST
Clinical Trials
Leadership
Join Us
Investors
▼
Overview
News & Events
▼
News Releases
Events & Presentations
Governance
▼
Overview
Executive Leadership
Board of Directors
Committee Composition
Stock Information
▼
Stock Quote & Chart
Financials
▼
SEC Filings
Resources
▼
Investor FAQs
Email Alerts
Contact IR
Contact
Publications + Posters
|
Bioorganic & Medicinal Chemistry Letters
June 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
Scott Throner, et al.
|
AACR Molecular Cancer Therapeutics
June 2025
Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency
Antoine Simoneau, et al.
|
AACR Molecular Cancer Therapeutics
June 2025
LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Lauren Catherine M. Martires, et al.
|
AACR Molecular Cancer Therapeutics
June 2025
CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Katherine Lazarides, et al.
|
AACR
April 2025
TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of solid tumors with MTAP loss
Kimberly J. Briggs, et al.
Learn more about our drug discovery programs and explore our pipeline.